GRCL - Gracell Biotechnologies to Participate in Four Upcoming Investor Conferences
SUZHOU, China and PALO ALTO, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that it will participate in the following upcoming conferences:
Goldman Sachs Asia Pacific Healthcare Forum 2021
One-on-one and small group meetings (virtual): November 15-17, 2021
For more information, please contact your Goldman Sachs representative.
8 th BioCentury-BayHelix China Healthcare Summit
In-person one-on-one and small group meetings (Shanghai, China): November 17, 2021
Panel - China Biotech CEO Blue Ribbon Roundtable: November 17, 2021, 14:30-15:15pm CST
For more information, please contact your Biocentury representative.
Jefferies London Healthcare Conference
One-on-one and small group meetings (virtual): November 18-19, 2021
Fireside Chat: available on-demand beginning on Thursday, November 18, 3:00am ET
Webcast link: https://ir.gracellbio.com/news-events/events-and-presentations
The replay of the fireside chat can be accessed through the “ News and Events ” section of the Gracell Investor website.
For more information, please contact your Jefferies representative.
20 th Morgan Stanley Annual Asia Pacific Summit
One-on-one and small group meetings (virtual): November 18-19, 2021
For more information, please contact your Morgan Stanley representative.
About Gracell
Gracell Biotechnologies Inc. ("Gracell") is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies. Leveraging its pioneering FasTCAR and TruUCAR technology platforms, Gracell is developing a rich clinical-stage pipeline of multiple autologous and allogeneic product candidates with the potential to overcome major industry challenges that persist with conventional CAR-T therapies, including lengthy manufacturing time, suboptimal production quality, high therapy cost and lack of effective CAR-T therapies for solid tumors. For more information on Gracell, please visit www.gracellbio.com
Follow @GracellBio on LinkedIn
Media contact
Marvin Tang
Investor contact
Gracie Tong